Diffuse alterations in synaptic protein expression following focal traumatic brain injury in the immature rat

2007 ◽  
Vol 23 (10) ◽  
pp. 1171-1179 ◽  
Author(s):  
G. T. Gobbel ◽  
C. Bonfield ◽  
E. B. Carson-Walter ◽  
P. D. Adelson
2021 ◽  
pp. 1-9
Author(s):  
Qinhan Hou ◽  
Hongmou Chen ◽  
Quan Liu ◽  
Xianlei Yan

Traumatic brain injury (TBI) can induce neuronal apoptosis and neuroinflammation, resulting in substantial neuronal damage and behavioral disorders. Fibroblast growth factors (FGFs) have been shown to be critical mediators in tissue repair. However, the role of FGF10 in experimental TBI remains unknown. In this study, mice with TBI were established via weight-loss model and validated by increase of modified neurological severity scores (mNSS) and brain water content. Secondly, FGF10 levels were elevated in mice after TBI, whereas intraventricular injection of Ad-FGF10 decreased mNSS score and brain water content, indicating the remittance of neurological deficit and cerebral edema in TBI mice. In addition, neuronal damage could also be ameliorated by stereotactic injection of Ad-FGF10. Overexpression of FGF10 increased protein expression of Bcl-2, while it decreased Bax and cleaved caspase-3/PARP, and improved neuronal apoptosis in TBI mice. In addition, Ad-FGF10 relieved neuroinflammation induced by TBI and significantly reduced the level of interleukin 1β/6, tumor necrosis factor α, and monocyte chemoattractant protein-1. Moreover, Ad-FGF10 injection decreased the protein expression level of Toll-like receptor 4 (TLR4), MyD88, and phosphorylation of NF-κB (p-NF-κB), suggesting the inactivation of the TLR4/MyD88/NF-κB pathway. In conclusion, overexpression of FGF10 could ameliorate neurological deficit, neuronal apoptosis, and neuroinflammation through inhibition of the TLR4/MyD88/NF-κB pathway, providing a potential therapeutic strategy for brain injury in the future.


2011 ◽  
Vol 28 (5) ◽  
pp. 763-774 ◽  
Author(s):  
Todd J. Kilbaugh ◽  
Sunita Bhandare ◽  
David H. Lorom ◽  
Manda Saraswati ◽  
Courtney L. Robertson ◽  
...  

2017 ◽  
Vol 34 (1) ◽  
pp. 220-234 ◽  
Author(s):  
Christopher R. Dorsett ◽  
Jennifer L. McGuire ◽  
Tracy L. Niedzielko ◽  
Erica A.K. DePasquale ◽  
Jaroslaw Meller ◽  
...  

Neurosurgery ◽  
2000 ◽  
Vol 47 (2) ◽  
pp. 510-511
Author(s):  
Steven A. Dutcher ◽  
Julie Pilitsis ◽  
Bill D. Underwood ◽  
Paul D. Walker ◽  
Fernando G. Diaz ◽  
...  

2013 ◽  
Vol 30 (24) ◽  
pp. 2066-2072 ◽  
Author(s):  
Courtney L. Robertson ◽  
Manda Saraswati ◽  
Susanna Scafidi ◽  
Gary Fiskum ◽  
Paula Casey ◽  
...  

2018 ◽  
Vol 29 (11) ◽  
pp. 4506-4518 ◽  
Author(s):  
Mustafa Q Hameed ◽  
Tsung-Hsun Hsieh ◽  
Leon Morales-Quezada ◽  
Henry H C Lee ◽  
Ugur Damar ◽  
...  

Abstract Traumatic brain injury (TBI) results in a decrease in glutamate transporter-1 (GLT-1) expression, the major mechanism for glutamate removal from synapses. Coupled with an increase in glutamate release from dead and dying neurons, this causes an increase in extracellular glutamate. The ensuing glutamate excitotoxicity disproportionately damages vulnerable GABAergic parvalbumin-positive inhibitory interneurons, resulting in a progressively worsening cortical excitatory:inhibitory imbalance due to a loss of GABAergic inhibitory tone, as evidenced by chronic post-traumatic symptoms such as epilepsy, and supported by neuropathologic findings. This loss of intracortical inhibition can be measured and followed noninvasively using long-interval paired-pulse transcranial magnetic stimulation with mechanomyography (LI-ppTMS-MMG). Ceftriaxone, a β-lactam antibiotic, is a potent stimulator of the expression of rodent GLT-1 and would presumably decrease excitotoxic damage to GABAergic interneurons. It may thus be a viable antiepileptogenic intervention. Using a rat fluid percussion injury TBI model, we utilized LI-ppTMS-MMG, quantitative PCR, and immunohistochemistry to test whether ceftriaxone treatment preserves intracortical inhibition and cortical parvalbumin-positive inhibitory interneuron function after TBI in rat motor cortex. We show that neocortical GLT-1 gene and protein expression are significantly reduced 1 week after TBI, and this transient loss is mitigated by ceftriaxone. Importantly, whereas intracortical inhibition declines progressively after TBI, 1 week of post-TBI ceftriaxone treatment attenuates the loss of inhibition compared to saline-treated controls. This finding is accompanied by significantly higher parvalbumin gene and protein expression in ceftriaxone-treated injured rats. Our results highlight prospects for ceftriaxone as an intervention after TBI to prevent cortical inhibitory interneuron dysfunction, partly by preserving GLT-1 expression.


Sign in / Sign up

Export Citation Format

Share Document